Carregant...
Combination therapy for metastatic renal cell carcinoma
Current therapy for metastatic clear cell renal cell carcinoma (RCC) consists of the serial administration of single agents. Combinations of VEGF and mTOR inhibitors have been disappointing in previous randomized trials. However, the combination of lenvatinib, a multitargeted agent that inhibits VEG...
Guardat en:
| Publicat a: | Ann Transl Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4791344/ https://ncbi.nlm.nih.gov/pubmed/27047959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2016.01.31 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|